title: Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
abstract: Sclerotic chronic GvHD (cGvHD) is one of the most severe complications after allo-hematopoietic stem cell transplantation (HSCT). Risk factors associated with this complication remain not very well defined. With the aim to define a pre-transplantation risk profile, we have conducted a French retrospective analysis in 705 consecutive patients between 2005 and 2010. Analyses to determine pre-transplantation risk factors included as variables: patient and donor age, kind of donor, HLA matching, ABO matching, sex-matching, diagnosis, stem cell source, gender, GvHD prophylaxis and antithymocyte globulin (ATG) in the conditioning regimen. The cumulative incidence of sclerotic cGvHD was 18% (95% CI, 16.6-19.6) 3 years after onset of cGvHD. In univariate analysis, we found a significantly lower number of sclerotic cGvHD form in patients transplanted from cord blood cells (P=0.0021), in patients with a one mismatched donor (P=0.041) and in patients who had received ATG in the conditioning regimen (P=0.002). In multivariate analysis, factors associated with an increased risk of sclerotic cGvHD were young patient age, multiple myeloma and PBSC as the stem cell source. ATG in conditioning regimen and cord blood unit as the stem cell source were associated with a lower risk.
authors.affiliation: Hematology Department, Groupement Hospitalier Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon EST, Pierre Bénite, France.
authors.forename: M Y
authors.initials: MY
authors.lastname: Detrait
authors.affiliation: Biostatistician, Clinical Research Unit, Department of Hematology, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre Bénite, France.
authors.forename: S
authors.initials: S
authors.lastname: Morisset
authors.affiliation: Blood and Marrow Transplantation Unit,Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Peffault de Latour
authors.affiliation: Service des Maladies du Sang, CHU Lille, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.affiliation: Blood and marrow transplantation Program, Hematology Department, Institut Paoli-Calmettes, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Crocchiolo
authors.affiliation: Hematology Department, Hôpital du Haut Levêque, Pessac, France.
authors.forename: R
authors.initials: R
authors.lastname: Tabrizi
authors.affiliation: Hematology Department, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France.
authors.forename: J-O
authors.initials: JO
authors.lastname: Bay
authors.affiliation: Hematology Department, Center Hospitalier Universitaire (CHU) de Nantes, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Chevalier
authors.affiliation: Hematology Department, Groupement Hospitalier Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon EST, Pierre Bénite, France.
authors.forename: F
authors.initials: F
authors.lastname: Barraco
authors.affiliation: Data management of SFGM-TC, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
authors.forename: N
authors.initials: N
authors.lastname: Raus
authors.affiliation: Hematology Department, Hôpital du Haut Levêque, Pessac, France.
authors.forename: S
authors.initials: S
authors.lastname: Vigouroux
authors.affiliation: Service des Maladies du Sang, CHU Lille, Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Magro
authors.affiliation: Hematology Department, Center Hospitalier Universitaire (CHU) de Nantes, Nantes, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: Hematology Department, Hôpital du Haut Levêque, Pessac, France.
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.affiliation: Blood and marrow transplantation Program, Hematology Department, Institut Paoli-Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.affiliation: Blood and Marrow Transplantation Unit,Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.affiliation: Hematology Department, Groupement Hospitalier Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon EST, Pierre Bénite, France.
authors.forename: M
authors.initials: M
authors.lastname: Michallet
mesh_terms: D064591:Allografts; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D002908:Chronic Disease; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D005602:France / Q000453:epidemiology; D006086:Graft vs Host Disease / Q000401:mortality* / Q000517:prevention & control; D006402:Hematologic Diseases / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D012598:Sclerosis; D019172:Transplantation Conditioning
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents